Grifols | GRFS - Assets


Grifols reported EUR23.15B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Alaunos Therapeutics USD 3.72M 1.01M Sep/2025
Arca Biopharma USD 488.62M 20.63M Dec/2025
aTyr Pharma USD 515.34M 408.68M Dec/2025
Bio Path USD 690K 56K Sep/2025
Brainstorm Cell Therapeutics USD 1.02M 358K Dec/2025
Capricor Therapeutics USD 355.95M 229.51M Dec/2025
Cara Therapeutics USD 39.02M 4.73M Sep/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Immunic USD 40.7M 20.72M Sep/2025
Infinity Pharmaceuticals USD 21.23M 8.72M Jun/2023
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
TherapeuticsMD USD 40.13M 1.96M Jun/2024